American Diabetes Association
Browse
cd23-0025_Supplementary_Material.pdf (365.17 kB)

Beneficial Effects of Control-IQ Automated Insulin Delivery in Basal-Bolus and Basal-Only Insulin Users With Type 2 Diabetes

Download (365.17 kB)
figure
posted on 2023-08-28, 18:38 authored by Carol J. Levy, Dan Raghinaru, Yogish C. Kudva, Keta Pandit, Thomas Blevins, Luis Casaubon, Donna Desjardins, Camilla M. Levister, Grenye O’Malley, Corey Reid, John Lum, Craig Kollman, Roy W. Beck

The t:slim X2 insulin pump with Control-IQ technology (Control-IQ) advanced hybrid closed-loop automated insulin delivery system was evaluated in this prospective single-arm trial. Thirty adults with type 2 diabetes using the Control-IQ system showed substantial glycemic improvement with no increase in hypoglycemia. Mean time in range (70–180 mg/dL) improved 15%, representing an increase of 3.6 hours/day, and mean glucose decreased by 22 mg/dL.

Funding

Tandem Diabetes Care, Inc

History

Usage metrics

    Clinical Diabetes

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC